Guillain-Barré syndrome laboratory tests

Jump to navigation Jump to search

Guillain-Barré syndrome Microchapters


Patient Information


Historical Perspective




Differentiating Guillain-Barré syndrome from other Diseases

Epidemiology and Demographics

Risk Factors


Natural history, Complications, and Prognosis


Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings



Echocardiography and Ultrasound

CT scan


Other Imaging Findings

Other Diagnostic Studies


Medical Therapy


Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Guillain-Barré syndrome laboratory tests On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Guillain-Barré syndrome laboratory tests

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical

US National Guidelines Clearinghouse

NICE Guidance

FDA on Guillain-Barré syndrome laboratory tests

CDC on Guillain-Barré syndrome laboratory tests

Guillain-Barré syndrome laboratory tests in the news

Blogs on Guillain-Barré syndrome laboratory tests

Directions to Hospitals Treating Guillain-Barré syndrome

Risk calculators and risk factors for Guillain-Barré syndrome laboratory tests

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.


Laboratory findings consistent with the diagnosis of Guillain Barre syndrome include: Elevated CSF protein level, normal CSF WBC count, normal CSF cell count (in some cases there is mildly elevated cell count) and serum IgG antibody to GQ1b in Miller Fisher syndrome.

Laboratory Findings


  1. Al-Hakem H, Doets AY, Stino AM, Zivkovic SA, Andersen H, Willison HJ; et al. (2023). "CSF Findings in Relation to Clinical Characteristics, Subtype, and Disease Course in Patients With Guillain-Barré Syndrome". Neurology. 100 (23): e2386–e2397. doi:10.1212/WNL.0000000000207282. PMID 37076309 Check |pmid= value (help).
  2. Yuki N, Hartung HP (June 2012). "Guillain-Barré syndrome". N. Engl. J. Med. 366 (24): 2294–304. doi:10.1056/NEJMra1114525. PMID 22694000.
  3. Nishimoto Y, Odaka M, Hirata K, Yuki N (March 2004). "Usefulness of anti-GQ1b IgG antibody testing in Fisher syndrome compared with cerebrospinal fluid examination". J. Neuroimmunol. 148 (1–2): 200–5. doi:10.1016/j.jneuroim.2003.11.017. PMID 14975602.
  4. Fokke C, van den Berg B, Drenthen J, Walgaard C, van Doorn PA, Jacobs BC (January 2014). "Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria". Brain. 137 (Pt 1): 33–43. doi:10.1093/brain/awt285. PMID 24163275.
  5. Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I (October 1993). "Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies". Neurology. 43 (10): 1911–7. PMID 8413947.

Template:WH Template:WS